Medtronic's SWOT analysis: medical device giant faces tariffs, sees growth in RDN

Medtronic (MDT) reported strong FY25 fourth-quarter sales growth of 5.4% organically and an 11% increase in EPS, with revenue reaching $33.54 billion, up 3.62% year-over-year; FY26 guidance projects 5% organic growth and a 7% increase in operating income, though EPS growth is expected to be lower due to a higher tax rate and tariffs. Key growth drivers include the Cardiovascular division, increasing adoption of Renal Denervation (RDN) technology, and progress with the Hugo surgical robot, while the planned spin-off of the diabetes segment is viewed as potentially value-unlocking, however increased tariffs and strong competition pose potential headwinds.

Analysis

Medtronic PLC (MDT) demonstrated strong operational performance concluding fiscal year 2025, reporting a 5.4% organic sales growth in the fourth quarter and an 11% increase in earnings per share (EPS), contributing to a 3.62% rise in last twelve months revenue to $33.54 billion. The company anticipates continued momentum into fiscal year 2026, projecting 5% organic growth and a 7% increase in operating income, excluding tariffs, with analysts expecting diluted EPS to reach $5.57. However, FY26 EPS growth is projected to be in the low single digits due to a 3% EPS headwind from a higher tax rate and refinancing costs, plus an additional 2-4% burden from potential tariffs. Key growth catalysts include the Cardiovascular division, particularly its Pulmonary Fibrosis Awareness products, and the increasing adoption of Renal Denervation (RDN) technology, supported by improving insurance coverage and positive clinical feedback. Further, Medtronic is advancing its Hugo surgical robot program, having met the primary endpoint in its IDE study and submitted for FDA approval in Q1, and recently received FDA approval for its smaller Simplera Sync sensor for the 780G insulin pump. The planned spin-off of its Diabetes segment, expected to materialize more fully in FY27, is viewed as a potential value-unlocking strategy. Despite these positives and a "GOOD" financial health score from InvestingPro, with the stock trading near its 52-week low and deemed slightly undervalued by InvestingPro's Fair Value analysis, Medtronic faces challenges. These include intense competition in the diabetes care market from BBNX and TNDM, concerns over the 780G pump's form factor, and the general competitive landscape of surgical robotics. The company has a 49-year history of dividend payments, currently yielding 3.52%, reflecting financial stability.

Key Decisions for Investors

• Investors should weigh Medtronic's solid Q4 FY25 performance, FY26 organic growth guidance of 5%, and potential undervaluation near its 52-week low against significant FY26 EPS headwinds from increased tariffs (2-4% impact) and higher tax rates.
• Monitor key growth drivers such as the adoption rate of Renal Denervation technology, the FDA approval process and subsequent market uptake of the Hugo surgical robot, and stabilization of market share in the Diabetes segment following the Simplera Sync launch.
• Consider the long-term implications of the Diabetes segment spin-off, anticipated to unlock value primarily from FY27 onwards, while acknowledging near-term competitive pressures in this segment and the execution risk associated with the separation.
• Evaluate the company's consistent dividend yield (3.52%) and long payment history as a component of total return, particularly in light of the projected low single-digit EPS growth for FY26.